SCHEMBL6186717

SCHEMBL6186717

CN(C)CCOc1cc(NS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 6/20 0.54
CACNA1H O95180 4/20 0.53
PGR P06401 2/20 0.52
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
FABP4 P15090 1/20 0.47
HRH3 Q9Y5N1 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 1/20 0.46
XBP1 P17861 1/20 0.46
HTT P42858 1/20 0.46
PLA2G7 Q13093 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
UTS2R Q9UKP6 1/20 0.45
ALOX15 P16050 1/20 0.45
AR P10275 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6174632 0.94 CACNA1B (0.53) CACNA1BCACNA1HPGRALDH1A1MAPT
SCHEMBL6177607 0.93 CACNA1B (0.55) CACNA1BCACNA1HPGRALDH1A1MAPT
SCHEMBL6177731 0.93 CACNA1B (0.65) CACNA1BCACNA1HPGRFABP4UTS2R
SCHEMBL6176052 0.93 CACNA1B (0.53) CACNA1BCACNA1HPGRALDH1A1MAPT
SCHEMBL6177543 0.91 CACNA1B (0.59) CACNA1BCACNA1HPGRFABP4UTS2R
SCHEMBL6178234 0.91 CACNA1B (0.54) CACNA1BCACNA1HPGRALDH1A1MAPT
SCHEMBL6176083 0.90 CACNA1B (0.57) CACNA1BCACNA1HHPGDUTS2R
SCHEMBL6179473 0.87 CACNA1B (0.54) CACNA1BCACNA1HPGRFABP4HPGD
SCHEMBL6542669 0.86 UTS2R (0.53) CACNA1BCACNA1HALDH1A1MAPTMEN1
SCHEMBL6542543 0.84 LMNA (0.56) CACNA1BCACNA1HALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399137-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-12-14 EP claimed
US-6849635-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2005-02-01 US claimed
US-20040152893-A1 Sulfonamides SMITHKLINE BEECHAM CORPORATION 2004-08-05 US claimed
EP-1399137-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-03-24 EP claimed
WO-2002089785-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
EP-1399137-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-12-14 EP disclosed
US-6849635-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2005-02-01 US disclosed
US-20040152893-A1 Sulfonamides SMITHKLINE BEECHAM CORPORATION 2004-08-05 US disclosed
EP-1399137-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-03-24 EP disclosed
WO-2002089785-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152893-A1 Sulfonamides UTS2R, PRSS2, STS CACNA1B 3246/4885CACNA1H 3106/4885PGR 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.